Neuromodulation of the Dorsal Genital Nerve in Patiënts with Persistent Genital Arousal Disorder

Neuromodulation of the Dorsal Genital Nerve in Patiënts with Persistent Genital Arousal Disorder - NemoPGAD

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON53294

Enrollment

Registered

2023-04-05

Start date

2023-04-26

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent Genital Arousal Syndrome

Interventions

Each subject will be administered daily neuromodulation for a total of three weeks, using UCon.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patiets diagnosed with PGAD

Exclusion criteria

Exclusion criteria: - Patients

Design outcomes

Primary

Measure	Time frame
Primary outcome measures is the effect of neuromodulation on PGAD symptoms.	—

Secondary

Measure	Time frame
Secondary outcome measures include session duration, stimulation level and frequency of neuromodulation; effect of neuromodulation on quality of life and on mental health; and experiences of using UCon.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 1, 2026